SCHEMBL15539798

SCHEMBL15539798

COC(=O)c1cc(=O)n(C)cc1Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.44
BAZ2B Q9UIF8 1/20 0.42
BAZ2A Q9UIF9 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
CYP1A2 P05177 4/20 0.42
CYP2C19 P33261 4/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2D6 P10635 1/20 0.42
NR4A2 P43354 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP3A4 P08684 1/20 0.39
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 1/20 0.38
LMNA P02545 2/20 0.38
TSHR P16473 2/20 0.38
HPGD P15428 1/20 0.38
MAP2K2 P36507 1/20 0.37
MAP2K1 Q02750 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21220747 0.80 LCK (0.43) BAZ2BBAZ2ASMN1; SMN2CYP1A2CYP2C19
SCHEMBL26235469 0.77 BRD4 (0.49) BRD4BAZ2BBAZ2ASMN1; SMN2NR4A2
SCHEMBL31133035 0.76 BAZ2B (0.69) BRD4BAZ2BBAZ2ASMN1; SMN2CYP1A2
SCHEMBL197110 0.75 SOS1 (0.50) NR4A2KDM4EMAPTKMT2AALDH1A1
SCHEMBL8240176 0.74 NR4A2 (0.42) BRD4SMN1; SMN2CYP1A2CYP2C19CYP2C9
SCHEMBL20605394 0.73 CFTR (0.47) BRD4BAZ2BBAZ2ANR4A2KDM4E
SCHEMBL20606256 0.73 BRD4 (0.45) BRD4BAZ2BBAZ2ASMN1; SMN2NR4A2
SCHEMBL23062566 0.73 MEN1 (0.54) SMN1; SMN2CYP1A2CYP2C19CYP2C9KDM4E
SCHEMBL30292702 0.73 KMT2A (0.38) BRD4SMN1; SMN2CYP1A2CYP2C19CYP2C9
SCHEMBL70159 0.73 CA1 (0.45) NR4A2KDM4EMAPTKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4727540-A2 FUSED BICYCLIC HETEROCYCLIC OR HETERO ARYL AMIDE COMPOUNDS Quantx Biosciences US, Inc. (US) 2026-04-22 EP disclosed
EP-4702017-A1 SARM1 MODULATORS, PREPARATIONS, AND USES THEREOF Sironax Ltd (KY) 2026-03-04 EP disclosed
US-20260022114-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE GILEAD SCIENCES, INC. 2026-01-22 US disclosed
EP-4676480-A1 INHIBITORS OF DNA POLYMERASE THETA Breakpoint Therapeutics GmbH (DE) 2026-01-14 EP disclosed
EP-4594316-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE Repare Therapeutics Inc. (CA) 2025-08-06 EP disclosed
US-20250026748-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA REPARE THERAPEUTICS INC. (CA) 2025-01-23 US disclosed
WO-2025016391-A1 THIAZOLE PYRAZINE COMPOUNDS AND USE THEREOF 南京再明医药有限公司 2025-01-23 WO disclosed
WO-2024259233-A2 FUSED BICYCLIC HETEROCYCLIC OR HETERO ARYL AMIDE COMPOUNDS QUANTX BIOSCIENCES US, INC. (US) 2024-12-19 WO disclosed
US-12139482-B2 Bicyclic pyridone lactams and methods of use thereof GENENTECH, INC. (US) 2024-11-12 US disclosed
WO-2024197401-A1 1,3,4-THIADIAZOL-2-YL CARBOXAMIDE AND 1,3-THIAZOL-2-YL CARBOXAMIDE COMPOUNDS AND USES THEREOF AS INHIBITORS OF HUMAN POLYMERASE THETA REPARE THERAPEUTICS INC. (CA) 2024-10-03 WO disclosed
US-20190241565-A1 BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF GENENTECH, INC. (US) 2019-08-08 US disclosed
WO-2018086605-A1 NITROGENOUS MACROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF 山东罗欣药业集团股份有限公司 2018-05-17 WO disclosed
EP-2858990-B1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBVIE INC (US) 2018-05-16 EP disclosed
WO-2018073193-A1 BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2018-04-26 WO disclosed
US-9561231-B2 Pyridinone and pyridazinone derivatives ABBVIE INC. (US) 2017-02-07 US disclosed
EP-2858990-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES AbbVie Inc. (US) 2015-04-15 EP disclosed
EP-2858982-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES AbbVie Inc. (US) 2015-04-15 EP disclosed
WO-2013185284-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBOTT LABORATORIES (US) 2013-12-19 WO disclosed
WO-2013188381-A1 PYRIDINONE AND PYRIDAZINONE DERIVATIVES ABBVIE INC. (US) 2013-12-19 WO disclosed
US-20130331382-A1 Pyridinone and Pyridazinone Derivatives ABBVIE INC. 2013-12-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260022114-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE POLK, POLQ, POLB BRD4 1141/4885BAZ2B 1163/4885BAZ2A 795/4885
US-20250026748-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (THIAZOLYL)])(SUBSTITUTED)CARBOXAMIDE COMPOUNDS AND USE THEREOF FOR INHIBITING HUMAN POLYMERASE THETA POLA1, POLL, POLD1 BRD4 1945/4885BAZ2B 916/4885BAZ2A 932/4885
US-20130331382-A1 Pyridinone and Pyridazinone Derivatives CYP4F3, CYP4B1, CYP4F11 BRD4 1281/4885BAZ2B 1662/4885BAZ2A 2277/4885
US-20190241565-A1 BICYCLIC PYRIDONE LACTAMS AND METHODS OF USE THEREOF CYP3A5, C5, PDXK BRD4 243/4885BAZ2B 326/4885BAZ2A 661/4885
US-12139482-B2 Bicyclic pyridone lactams and methods of use thereof CYP3A5, C5, PDXK BRD4 243/4885BAZ2B 326/4885BAZ2A 661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.